OP \$190.00 5561401

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 ETAS ID: TM751180

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT

CONVEYING PARTY DATA

Name	Formerly	Execution Date	Entity Type
MELINTA SUBSIDIARY CORP.		08/23/2022	Corporation: DELAWARE

RECEIVING PARTY DATA

Name:	Silicon Valley Bank
Street Address:	3003 Tasman Drive, HF 150
City:	Santa Clara
State/Country:	CALIFORNIA
Postal Code:	95054
Entity Type:	Corporation: CALIFORNIA

PROPERTY NUMBERS Total: 7

Property Type	Number	Word Mark
Registration Number:	5561401	BAXDELA
Registration Number:	5725767	BAXDELA
Registration Number:	4653983	MELINTA
Registration Number:	4939738	MELINTA THE ANTIBIOTICS COMPANY
Registration Number:	4713360	MELINTA THERAPEUTICS
Registration Number:	5752179	MELINTASSIST
Registration Number:	5662658	MELINTASSIST

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 800-494-5225

Email: ipteam@cogencyglobal.com

Correspondent Name: Stewart Walsh

Address Line 1: 1025 Connecticut Ave NW, Suite 712

Address Line 2: COGENCY GLOBAL Inc.
Address Line 4: Washington, D.C. 20036

ATTORNEY DOCKET NUMBER: 1767838 TM C

TRADEMARK REEL: 007821 FRAME: 0425

900716165

NAME OF SUBMITTER:	Gwendolyn Mecsas
SIGNATURE:	/Gwendolyn Mecsas/
DATE SIGNED:	08/25/2022

Total Attachments: 49

- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page1.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page2.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page3.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page4.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page5.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page6.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page7.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page8.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page9.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page10.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page11.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page12.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page13.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page14.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page15.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page16.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page17.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page18.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page19.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page20.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page21.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page22.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page23.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page24.tif

- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page25.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page26.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page27.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page28.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page29.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page30.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page31.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page32.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page33.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page34.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page35.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page36.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page37.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page38.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page39.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page40.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page41.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page42.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page43.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page44.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page45.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page46.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page47.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page48.tif
- source=C Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp)- Melinta (3rd LMA)#page49.tif

AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT

This Amended and Restated Intellectual Property Security Agreement (this "Agreement") is entered into as of August 23, 2022, by and between SILICON VALLEY BANK, a California corporation ("Bank") and MELINTA SUBSIDIARY CORP., a Delaware corporation ("Grantor"). This Agreement amends and restates in its entirety, and replaces, that certain Intellectual Property Security Agreement dated as of December 22, 2020, by and between Grantor and Bank (the "Prior Agreement").

RECITALS

- Bank has agreed to make certain advances of money and to extend certain financial accommodations to Grantor (the "Loans") in the amounts and manner set forth in that certain Loan and Security Agreement by and among Bank, Grantor, MELINTA THERAPEUTICS, LLC, a Delaware limited liability company ("Melinta"), TARGANTA THERAPEUTICS CORPORATION, a Delaware corporation ("Targanta"), and REMPEX PHARMACEUTICALS, INC., a Delaware corporation ("Rempex", and together with Grantor, Melinta and Targanta, individually and collectively, jointly and severally, "Borrower") dated as of December 22, 2020, as amended by that certain First Amendment to Loan and Security Agreement by and between Bank and Borrower dated as of May 3, 2022, as further amended by that certain Second Amendment to Loan and Security Agreement by and between Bank and Borrower dated as of July 25, 2022, and as further amended by that certain Third Amendment to Loan and Security Agreement by and between Bank and Borrower dated as of the date hereof (as the same has been, and as may be further amended, modified or supplemented from time to time, the "Loan Agreement"; capitalized terms used herein are used as defined in the Loan Agreement). Bank is willing to make the Loans to Grantor, but only upon the condition, among others, that Grantor shall grant to Bank a security interest in its Copyrights, Trademarks, and Patents (as each term is described below) to secure the obligations of Grantor to Bank.
- B. Pursuant to the terms of the Loan Agreement, Grantor has granted to Bank a security interest in all of Grantor's right, title and interest, whether presently existing or hereafter acquired, in, to and under all of the Collateral.

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, and intending to be legally bound, as collateral security for the prompt and complete payment when due of Borrower's obligations to Bank, Grantor hereby represents, warrants, covenants and agrees as follows:

AGREEMENT

1. <u>Grant of Security Interest.</u> Subject to the terms and conditions of the Loan Agreement, to secure Borrower's obligations to Bank, Grantor grants and pledges to Bank a security interest in all of Grantor's right, title and interest in, to and under its intellectual property

1

(all of which shall collectively be called the "Intellectual Property Collateral"), including, without limitation, the following:

- (a) Any and all copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation those set forth on Exhibit A attached hereto (collectively, the "Copyrights");
- (b) Any and all trade secrets and trade secret rights, including, without limitation, any rights to unpatented inventions, know-how and operating manuals now or hereafter existing, created, acquired or held;
- (c) Any and all design rights that may be available to Grantor now or hereafter existing, created, acquired or held;
- (d) All patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the "Patents");
- (e) Any trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of Grantor connected with and symbolized by such trademarks, including without limitation those set forth on <u>Exhibit C</u> attached hereto (collectively, the "**Trademarks**");
 - (f) [Reserved];
- (g) Any and all claims for damages by way of past, present and future infringements of any of the rights included above, with the right, but not the obligation, to sue for and collect such damages for said use or infringement of the intellectual property rights identified above;
- (h) All licenses or other rights to use any of the Copyrights, Patents, or Trademarks and all license fees and royalties arising from such use to the extent permitted by such license or rights;
- (i) All amendments, extensions, renewals and extensions of any of the Copyrights, Trademarks, or Patents; and
- (j) All proceeds and products of the foregoing, including without limitation all payments under insurance or any indemnity or warranty payable in respect of any of the foregoing.

Notwithstanding anything to the contrary herein, the Intellectual Property Collateral shall not include any United States intent-to-use trademark or service mark applications filed pursuant to Section 1(b) of the Lanham Act, 15 U.S.C. § 1051, at all times prior to the filing of a "Statement of Use" pursuant to Section 1(d) of the Lanham Act or an "Amendment to Allege Use" pursuant

to Section 1(c) of the Lanham Act with respect thereto with the United States Patent and Trademark Office or otherwise.

- 2. <u>Recordation</u>. Grantor authorizes the Commissioner for Patents, the Commissioner for Trademarks and the Register of Copyrights and any other government officials of the United States to record and register this Agreement upon request by Bank.
- 3. <u>Authorization</u>. Grantor hereby authorizes Bank to (a) modify this Agreement unilaterally by amending the exhibits to this Agreement to include any Intellectual Property Collateral which Grantor obtains subsequent to the date of this Agreement, and (b) file a duplicate original of this Agreement containing amended exhibits reflecting such new Intellectual Property Collateral.
- 4. <u>Loan Documents</u>. This Agreement has been entered into pursuant to and in conjunction with the Loan Agreement, which is hereby incorporated by reference. The provisions of the Loan Agreement shall supersede and control over any conflicting or inconsistent provision herein. The rights and remedies of Bank with respect to the Intellectual Property Collateral are as provided by the Loan Agreement and related documents, and nothing in this Agreement shall be deemed to limit such rights and remedies.
- 5. <u>Execution in Counterparts</u>. This Agreement may be executed in counterparts (and by different parties hereto in different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract. Delivery of an executed counterpart of a signature page to this Agreement by facsimile or in electronic (i.e., "pdf" or "tif" format) shall be effective as delivery of a manually executed counterpart of this Agreement.
- 6. <u>Successors and Assigns</u>. This Agreement will be binding on and shall inure to the benefit of the parties hereto and their respective successors and assigns.
- Grantor and Bank hereby agree that, effective upon the 7. Prior Agreement. execution and delivery of this Agreement by each such party, the terms and provisions of the Prior Agreement shall be and hereby are amended, restated and superseded in their entirety by the terms and provisions of this Agreement. Nothing herein contained shall be construed as a substitution or novation of the obligations of Grantor outstanding under the Prior Agreement or instruments securing the same, which obligations shall remain in full force and effect, except to the extent that the terms thereof are modified hereby or by instruments executed concurrently herewith. Nothing expressed or implied in this Agreement shall be construed as a release or other discharge of Grantor from any of the obligations or liabilities under the Prior Agreement. Grantor hereby confirms and agrees that to the extent that the Prior Agreement purports to assign or pledge to the Bank, or to grant to Bank a security interest in or lien on, any collateral as security for the Obligations, such pledge, assignment or grant of the security interest or lien is hereby ratified and confirmed in all respects and shall remain effective as of the first date it became effective.
- 8. <u>Governing Law.</u> This Agreement and any claim, controversy, dispute or cause of action (whether in contract or tort or otherwise) based upon, arising out of or relating to this Agreement and the transactions contemplated hereby and thereby shall be governed by, and construed in accordance with, the laws of the United States and the State of New York, without

giving effect to any choice or conflict of law provision or rule (whether of the State of New York or any other jurisdiction).

[Signature page follows.]

4

IN WITNESS WHEREOF, the parties have caused this Agreement to be duly executed by its officers thereunto duly authorized as of the first date written above.

GRANTOR:

MELINTA SUBSIDIARY CORP.

By: Unistine Miller

Name: Christine Ann Miller

Title: President and Chief Executive Officer

BANK:

SILICON VALLEY BANK

By: John Sansone

Name: John Sansone

Title: Vice President

[Signature Page to Amended and Restated Intellectual Property Security Agreement (Subsidiary Corp.)]

EXHIBIT A

Copyrights

DescriptionRegistration/
ApplicationRegistration/
ApplicationNumberDate

None.

EXHIBIT B

Patents

		H2000000000000000000000000000000000000	***************************************		
Description	Country	App. No.	Filing Date	Patent No.	Issue Date
METHODS OF TREATING	United States of	17/406805	19-Aug-		
INFECTIONS IN	America		2021		
OVERWEIGHT AND					
OBESE PATIENTS USING					
ANTIBIOTICS					
METHODS OF TREATING	United States of	14/775465	11-Sep-2015		
INFECTIONS IN	America		ı		
OVERWEIGHT AND					
OBESE PATIENTS USING					
ANTIBIOTICS					
METHODS OF TREATING	Taiwan	103109491	14-Mar-	1641372	21-Nov-2018
INFECTIONS IN			2014		
OVERWEIGHT AND					
OBESE PATIENTS USING					
ANTIBIOTICS					
METHODS OF TREATING	Turkey	2015/14167	14-Mar-		
INFECTIONS IN			2014		
OVERWEIGHT AND					
OBESE PATIENTS USING					
ANTIBIOTICS					
METHODS OF TREATING	Mexico	MX/a/2015/011760	14-Mar-	388561	08-Dec-2021
INFECTIONS IN			2014		
OVERWEIGHT AND					
OBESE PATIENTS USING					
ANTIBIOTICS					
METHODS OF TREATING	Korea, Republic of	10-2015-7029301	14-Mar-	10-2237887	02-Apr-2021
INFECTIONS IN			2014		
OVERWEIGHT AND					
OBESE PATIENTS USING					

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
ANTIBIOTICS					
METHODS OF TREATING INFECTIONS IN	Japan	2016-502372	14-Mar- 2014	6617097	15-Nov-2019
OVERWEIGHT AND					
OBESE PATIENTS USING					
METHODS OF TREATING	Hong Kong	16107660.6	14-Mar-		
INFECTIONS IN	,		2014		
OBESE PATIENTS USING					
ANTIBIOTICS					
METHODS OF TREATING	Gulf Cooperation	26770	16-Mar-		
INFECTIONS IN	Council		2014		
OVERWEIGHT AND					
ANTIBIOTICS					
METHODS OF TREATING	European Patent	14768456.7	14-Mar-		
INFECTIONS IN	Convention		2014		
OVERWEIGHT AND					
OBESE PATIENTS USING					
ANTIBIOTICS METHODS OF TREATING	Canalo	200/207	14 Mo:	2004297	07 Dog 2021
INFECTIONS IN	Canada	2001001	2014	E701507	0. 000 000
OVERWEIGHT AND					
OBESE PATIENTS USING					
ANTIBIOTICS					
METHODS OF TREATING	Brazil	BR112015023044-	14-Mar-		
INFECTIONS IN		0	2014		
OVERWEIGHT AND					
OBESE PATIENTS USING					
ANTIBIOTICS					

ANTIMICROBIAL COMPOSITIONS WITH EFFERVESCENT AGENTS	PHARMACEUTICAL COMPOSITION AND USE THEREOF	PHARMACEUTICAL COMPOSITION AND USE THEREOF	ANTIMICROBIAL EFFERVESCENT FORMULATION	ANTIMICROBIAL COMPOSITIONS WITH EFFERVESCENT AGENTS	METHODS OF TREATING INFECTIONS IN OVERWEIGHT AND OBESE PATIENTS USING ANTIBIOTICS	Description				
San Marino	El Salvador	El Salvador	Turkey	Turkey	Taiwan	Taiwan	Uruguay	Vietnam	United Arab Emirates	Country
19165084.5	20200026765	20200026711	15810507.2	19165084.5	104119676	108140999	36.184	1-2017-00201	P1238/13	App. No.
19-Jun-2015	19-Jun-2015	19-Jun-2015	19-Jun-2015	19-Jun-2015	18-Jun-2015	18-Jun-2015	22-Jun-2015	19-Jun-2015	14-Mar- 2014	Filing Date
3581180	00090		3157510	3581180	1705814	1732337		29640		Patent No.
04-Aug-2021	08-Feb-2021		27-Mar-2019	04-Aug-2021	01 -0 ct-2020	01-Jul-2021		30-Aug-2021		Issue Date

Description	Country	Ann No	Filing Date	Patent No	Issue Date
ANTIMICROBIAL	San Marino	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
ANTIMICRORIAL	Slovakia	19165084 5	19-Մա-2015	3581180	04-Ano-2021
COMPOSITIONS WITH					(
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Slovakia	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Slovenia	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Slovenia	15810507.2	19-Jun-2015	3157510	27-Mar-2019
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Sweden	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					(
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Sweden	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Serbia	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					ı
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Serbia	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Romania	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					,
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Romania	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
ANTIMICROBIAL	Portugal	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					
ANTIMICROBIAL	Portugal	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
ANTIMICROBIAL	Poland	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					(
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Poland	15810507.2	19-Jun-2015	3157510	27-Mar-2019
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Philippines	0000000	19-Jun-2015		
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Philippines	1/2016/502548	19-Jun-2015		
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Peru	000031-2021/DIN	19-Jun-2015		
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Peru	002748-2016/DIN	19-Jun-2015	10603	17-Mar-2021
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	New Zealand	727638	19-Jun-2015		
FEFERVESCENT AGENTS					
ANTIMICROBIAL	Norway	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Norway	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
ANTIMICROBIAL	Netherlands	19165084.5	19-Jun-2015	3581180	04-Aug-2021
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Netherlands	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
ANTIMICROBIAL	Nicaraona	2016-000179	19-Jun-2015		
COMPOSITIONS WITH	Ċ		;		
EFFERVESCENT AGENTS					
ANTIMICROBIAL COMBOSITIONS WITH	Mexico	MX/a/2021/010727	19-Jun-2015		
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Mexico	MX/a/2019/012608	19-Jun-2015	386171	14-Sep-2021
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Mexico	MX/a/2016/017350	19-Jun-2015	368940	21 -O ct-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Malta	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Malta	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	North Macedonia	19165084.5	19-Jun-2015	3581180	04-Aug-2021
EFFERVESCENT AGENTS					
ANTIMICROBIAL	North Macedonia	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Monaco	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					

ANTIMICROBIAL COMPOSITIONS WITH EFFERVESCENT AGENTS	ANTIMICROBIAL COMPOSITIONS WITH EFFERVESCENT AGENTS	ANTIMICROBIAL COMPOSITIONS WITH EFFERVESCENT AGENTS ANTIMICROBIAL	ANTIMICROBIAL COMPOSITIONS WITH EFFERVESCENT AGENTS	Description							
Italy	Japan	Japan	Liechtenstein	Lithuania	Lithuania	Luxembourg	Luxembourg	Latvia	Latvia	Monaco	Country
19165084.5	2016-574040	2020-121083	15810507.2	15810507.2	19165084.5	15810507.2	19165084.5	15810507.2	19165084.5	15810507.2	App. No.
19-Jun-2015	19-Jun-2015	19-Jun-2015	19-Jun-2015	19-Jun-2015	19-Jun-2015	19-Jun-2015	19-Jun-2015	19-Jun-2015	19-Jun-2015	19-Jun-2015	Filing Date
3581180	6995479	6995479	3157510	3157510	3581180	3157510	3581180	3157510	3581180	3157510	Patent No.
04-Aug-2021	17-Dec-2021	17-Dec-2021	27-Mar-2019	27-Mar-2019	04-Aug-2021	27-Mar-2019	04-Aug-2021	27-Mar-2019	04-Aug-2021	27-Mar-2019	Issue Date

Description	Country	Ann No	Filing Date	Patent No	Issue Date
ANTIMICROBIAL	Italy	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH	,				
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Iceland	19165084.5	19-Jun-2015	3581180	04-Aug-2021
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Iceland	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Ireland	19165084.5	19-Jun-2015	3581180	04-Aug-2021
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Ireland	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Hungary	19165084.5	19-Jun-2015	3581180	04-Aug-2021
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Hungary	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Croatia	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Croatia	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Honduras	HN/P/2016/002686	19-Jun-2015	6271	15-Dec-2021
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Hong Kong	42022054703.8	19-Jun-2015		
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					

Description		Ann No	Filing Date	Patent No.	Isone Date
ANTIMICROBIAL	Hong Kong	42020009485.2	19-Jun-2015		
COMPOSITIONS WITH					
ANTIMICROBIAL	Hong Kong	17109792.2	19-Jun-2015	HK1236006	31-Jan-2020
COMPOSITIONS WITH	,				
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Guatemala	A-2016-000261	19-Jun-2015		
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Greece	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL COMPOSITIONS WITH	Greece	15810507.2	19-Jun-2015	3157510	27-Mar-2019
EFFERVESCENT AGENTS					
ANTIMICROBIAL	United Kingdom	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	United Kingdom	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	France	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	France	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Finland	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Finland	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					

Description	Country	Ann No	Filing Date	Patent No	Icena Data
ANTIMICROBIAL	Spain	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH	,				(
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Spain	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
ANTIMICROBIAL	European Patent	21188004.2	19-Jun-2015		
COMPOSITIONS WITH	Convention				
EFFERVESCENT AGENTS					
ANTIMICROBIAL	European Patent	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH	Convention				
EFFERVESCENT AGENTS					
COMPOSITIONS WITH	Estonia	19165084.5	19-Jun-2015	3581180	04-Aug-2021
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Estonia	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Ecuador	IEPI-2016-95540	19-Jun-2015		
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Eurasian Patent	201692532	19-Jun-2015	034152	09-Jan-2020
COMPOSITIONS WITH	Organization				
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Denmark	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Denmark	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Germany	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
ANTIMICROBIAL	Germany	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Czech Republic	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					
ANTIMICROBIAL	Czech Republic	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH	•				
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Cyprus, Republic	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH	of				
ANTINICACENI AGENIS	Comma Damiblia	150105070	10 1 2015		27 Mar 2010
COMPOSITIONS WITH	of	13810307.2	19 -J un-2015	9107910	27-1v1d1-2019
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Costa Rica	2020-0565	19-Jun-2015		
COMPOSITIONS WITH					
EFFERVESCENI AGENIS					
ANTIMICROBIAL	Costa Rica	2016-0592	19-Jun-2015		
EFFERVESCENT AGENTS					
USE OF A	China (People's	202210565182.1	19-Jun-2015		
PHARMACEUTICAL	Republic)				
COMPOSITION IN THE					
MANUFACTURE OF A					
MEDICAMENT FOR					
TREATING, PREVENTING					
OR REDUCING THE RISK					
OF A BACTERIAL					
INFECTION					
ANTIMICROBIAL	China (People's	201580044451.8	19-Jun-2015		
COMPOSITIONS WITH	Republic)				
EFFERVESCENT AGENTS					

, ,	-	P 4	7		7
Description	Chil	02152 2020	10 I::: 2015	Fatentivo.	Issue Date
COMPOSITIONS WITH	Cilia				
AN ORAL	Chile	03273-2016	19-Jun-2015		
PHARMACEUTICAL					
COMPOSITION					
COMPRISING					
DELAFLOXACIN OR ITS					
PHARMACEUTICALLY					
ACCEPTABLE SALT AND					
AN EFFERVESCENT					
AGENT COMPRISING A					
MIXTURE OF SODIUM					
BICARBONATE, SODIUM					
DIHYDROGEN					
PHOSPHATE AND CITRIC					
ACID; AND ITS USE TO					
TREAT, PREVENT, OR					
REDUCE					
ANTIMICROBIAL	Switzerland	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					ı
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Switzerland	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Canada	2952950	19-Jun-2015		
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Brazil	BR122020019725-	19-Jun-2015		
COMPOSITIONS WITH		0			
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Brazil	BR112016029761-	19-Jun-2015		
COMPOSITIONS WITH		0			
EFFERVESCENT AGENTS					

Description	Country	Ann No	Filino Date	Patent No	Issue Date
ANTIMICROBIAL	Bulgaria	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					
ANTIMICROBIAL	Bulgaria	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH	1				
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Belgium	19165084.5	19-Jun-2015	3581180	04-Aug-2021
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Belgium	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL COMPOSITIONS WITH	Australia	2021286284	19-Jun-2015		
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Australia	2020256457	19-Jun-2015	2020256457	13-Jan-2022
COMPOSITIONS WITH					
ANTIMICA OBIAT	Asset	2015276057	10 1 2015	2015276057	05 Nov. 2020
COMPOSITIONS WITH	Australia	2013270334	17-3411-2013	2013270334	07-1404-7070
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Austria	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Austria	15810507.2	19-Jun-2015	3157510	27-Mar-2019
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					
ANTIMICROBIAL	Argentina	P150101976	19-Jun-2015		
EFFERVESCENT					
FORMULATION					
ANTIMICROBIAL	Albania	19165084.5	19-Jun-2015	3581180	04-Aug-2021
COMPOSITIONS WITH					
EFFERVESCENT AGENTS					

		45566556666888866668888866688888666888888			000000000000000000000000000000000000000
Description	Country	App. No.	Filing Date	Patent No.	Issue Date
ANTIMICROBIAL	Albania	15810507.2	19-Jun-2015	3157510	27-Mar-2019
EFFERVESCENT AGENTS					
ANTIMICROBIAL	South Africa	2011/04108	12-Nov-	2011/04108	26-Sep-2012
COMPOSITIONS			2009		
KIT COMPRISING	Vietnam	1-2020-00265	12-Nov-		
ANTIMICROBIAL			2009		
COMPOSITIONS					
ANTIMICROBIAL	Vietnam	1-2011-01509	12-Nov-	23801	21-Apr-2020
COMPOSITIONS			2009		,
ANTIMICROBIAL	United States of	17/405772	18-Aug-		
COMPOSITIONS	America		2021		
ANTIMICROBIAL	United States of	16/425580	29-May-		
COMPOSITIONS	America		2019		
ANTIMICROBIAL	Ukraine	a201107519	12-Nov- 2009	102709	12-Aug-2013
ANTIMICROBIAL	El Salvador	2011003907	12-Nov-		
COMPOSITIONS			2009		
ANTIMICROBIAL	Singapore	201103403-0	12-Nov-	171235	24-Jun-2015
COMPOSITIONS			2009		
ANTIMICROBIAL	Philippines	1-2011-500932	12-Nov-	1-2011-500932	09-May-2017
FORMULATION FOR	Peru	002523-2015	12-Nov-	10371	17-Nov-2020
INTRAVENOUS			2009		
ADMINISTRATION					
INCLUDING					
DELAFLOXACIN OR A					
PHARMACEUTICALLY					
ACCEPTABLE SALT					
THEREOF AND					
HYDROXYPROPYL-BETA-					
CICEODEXIM					

Description FORMULATION FOR INTRAVENOUS ADMINISTRATION COMPRISING DELAFLOXACIN OR A PHARMACEUTICALLY ACCEPTABLE SALT	Peru	App. No. 001038-2011	Filing Date 12-Nov- 2009	Patent No. 7756	1ssue Date 05-Feb-2016
SULFOBUTYL ETHER					
ANTIMICROBIAL COMPOSITIONS	New Zealand	593345	12-Nov- 2009	593345	30-Jul-2013
ANTIMICROBIAL COMPOSITIONS	Nicaragua	2011-000097	12-Nov- 2009	2625 RPI	10-Oct-2017
ANTIMICROBIAL COMPOSITIONS	Malaysia	PI2020004141	2009 2009		
ANTIMICROBIAL COMPOSITIONS	Malaysia	PI2015002638	12-Nov- 2009	MY-188453-A	09-Dec-2021
ANTIMICROBIAL COMPOSITIONS	Malaysia	PI2011002096	12-Nov- 2009	MY-161597-A	28-Apr-2017
ANTIMICROBIAL COMPOSITIONS	Mexico	MX/a/2011/005117	12-Nov- 2009	327684	09-Feb-2015
ANTIMICROBIAL COMPOSITIONS	Morocco	PV/33932	12-Nov- 2009	32931	02-Jan-2012
ANTIMICROBIAL COMPOSITIONS	Korea, Republic of	10-2011-7013641	12-Nov- 2009	10-1767689	07-Aug-2017
ANTIMICROBIAL COMPOSITIONS	Japan	2016-168777	12-Nov- 2009	6407221	28-Sep-2018
ANTIMICROBIAL COMPOSITIONS	Japan	2011-536469	12-Nov- 2009	6063123	22-Dec-2016
ANTIMICROBIAL COMPOSITIONS	India	2465/KOLNP/2011	12-Nov- 2009		

			7.E		
ANTIMICEODIAI	Leed	212791	10 Nov.	212701	20 Mar 2017
COMPOSITIONS	101001		2009		CO IVERS ELOTS
COMPRISING A					
QUINOLONE					
CARBOXYLIC ACID					
DERIVATIVE AND					
CYCLODEXTRIN, AND					
USES THEREOF					
ANTIMICROBIAL	Indonesia	W-00201102140	12-Nov-	IDP000046145	02-Jun-2017
COMPOSITIONS			2009		
PHARMACEUTICAL	Honduras	2011-001294	12-Nov-	5848	18-Aug-2017
COMPOSITIONS			2009		
DELVELON COLUMN					
CVCI ODEVEDING					
ANTIMICROBIAL	Hone Kone	16101991 9	12-Nov-	HK1213821	22-Iun-2018
COMPOSITIONS	(2009		
ANTIMICROBIAL	Hong Kong	14109793.4	12-Nov-	HK1196530	20-Oct-2017
COMPOSITIONS			2009		
ANTIMICROBIAL	Hong Kong	12102144.7	12-Nov-		
COMPOSITIONS			2009		
ANTIMICROBIAL	Guatemala	A-2011-00119	12-Nov-		
COMPOSITIONS			2009		
ANTIMICROBIAL	European Patent	9826758.6	12-Nov-		
COMPOSITIONS	Convention		2009		
ANTIMICROBIAL	Egypt	736/2011	12-Nov-		
COMPOSITIONS			2009		
ANTIMICROBIAL	Ecuador	SP-11-11119	12-Nov-		
COMPOSITIONS			2009		
ANTIMICROBIAL	Eurasian Patent	201170689	12-Nov-	025637	30-Jan-2017
COMPOSITIONS	Organization		2009		
ANTIMICROBIAL	Algeria	110404	12-Nov- 2009	7898	30-Apr-2012

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
ANTIMICROBIAL	Costa Rica	2011-0320	12-Nov-	3345	09-Mar-2017
COMPOSITIONS			2009		
ANTIMICROBIAL	Chile	01121-2011	12-Nov-	CL53.555	14-Dec-2016
COMPOSITIONS			2009		
ANTIMICROBIAL	Canada	2743419	12-Nov-	2743419	14-Feb-2017
COMPOSITIONS			2009		
ANTIMICROBIAL	Brazil	BR122020021551-	12-Nov- 2009	BR122020021551-8	21-Sep-2021
ANTIMICROBIAL	Brazil	PI0921705-3	12-Nov-	PI0921705-3	19-Jan-2021
COMPOSITIONS			2009		
ANTIMICROBIAL	Australia	2009314072	12-Nov-	2009314072	03-Nov-2016
COMPOSITIONS			2009		
ANTIMICROBIAL	United Arab	P477/11	12-Nov-	3743	29-Jun-2021
COMPOSITIONS	Emirates		2009		
PROCESS FOR MAKING	United States of	14/743365	18-Jun-2015	RE46617	28-Nov-2017
QUINOLONE COMPOUNDS	America				
PROCESS FOR MAKING	United States of	13/937488	09-Jul-2013	8871938	28-Oct-2014
QUINOLONE COMPOUNDS	America				
PROCESS FOR MAKING QUINOLONE	Turkey	17163383.7	23-Sep-2009	3214083	16-Sep-2020
COMPOUNDS					
PROCESS FOR MAKING	Slovakia	PDO 2-2021	12-Feb-2021		
COMPOUNDS					
PROCESS FOR MAKING	Slovenia	C202140002	11-Feb-2021	202140002	15-Mar-2021
QUINOLONE					
PROCESS FOR MAKING	Sweden	SPC2190500-5	16-Feb-2021	2190500-5	24-Mar-2022
QUINOLONE					
COMPOUNDS					

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Romania	C20210002	11-Feb-2021		
PROCESS FOR MAKING QUINOLONE	Portugal	1069	23-Feb-2021	1069	26-Nov-2021
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Poland	DPO.0670	24-Feb-2021		
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Norway	2021006	15-Feb-2021		
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Netherlands	301091	04-Feb-2021	301091	03-Aug-2021
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Malta	181/2021	12-Feb-2021	181/2021	08-Mar-2021
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Latvia	CLV20210002	08-Feb-2021	CLV20210002	20-Jun-2021
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Luxembourg	LUC00196	10-Feb-2021	LUC00196	14-Dec-2021
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Lithuania	PA2021002	17-Feb-2021	PA 2021 002	09-Mar-2022
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Italy	132021000000011	16-Feb-2021	132021000000011	05-Mar-2021
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Iceland	SPC329	09-Feb-2021		

January 1				J .+	T 7:4;
PROCESS FOR MAKING	Treland	2021/002	15-Feb-2021	Latelli 140.	TSSUE DATE
QUINOLONE					
DELAFLOXACIN OR A	Hungary	S2100004	10-Feb-2021	S000571	09-Nov-2021
SALT OR ESTER					
THEREOF, INCLUDING					
MEGLUMINE					
PROCESS FOR MAKING	Croatia	S20210002	02-Feb-2021		
QUINOLONE					
COMPOUNDS					
OUINOLONE	Greece	20210800002	09-Feb-2021	8000856	01-Mar-2022
COMPOUNDS					
PROCESS FOR MAKING	United Kingdom	SPC/GB20/073	18-Dec-2020		
COMPOUNDS					
PROCESS FOR MAKING	France	21C1006	09-Feb-2021	21C1006	10-Jan-2022
QUINOLONE					
COMPOUNDS	Findam J	C20210002	16 Eat 2021		
QUINOLONE	riniand	C20210002	10-160-2021		
COMPOUNDS					
DELAFLOXACIN OR A	Spain	C202130010	22-Feb-2021	202130010	29-Oct-2021
SALT OR ESTER					
THEREOF, INCLUDING					
MEGITIMINE					
PROCESS FOR MAKING	Estonia	C20210002	15-Feb-2021		
QUINOLONE					
COMPOUNDS					
PROCESS FOR MAKING	Denmark	CA202100002	10-Feb-2021		
QUINOLONE					

Description	Country	App No	Filing Date	Patent No	Icema Data
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Germany	122021000010.0	16-Feb-2021		
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Czech Republic	SPC/CZ2021/734	15-Feb-2021		
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Cyprus, Republic of	SPCMCY2021004	10-Feb-2021	SPCMCY2021004	26-Feb-2021
DELAFLOXACIN	Switzerland	C03214083/01	24-Feb-2021	C03214083/01	06-Dec-2021
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Bulgaria	BG/S/2021/6	16-Feb-2021		
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Belgium	2021C/504	09-Feb-2021		
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Austria	SZ5/2021	10-Feb-2021	SZ5/2021	19-Apr-2021
PROCESS FOR MAKING QUINOLONE COMPOUNDS	San Marino	17163383.7	23-Sep-2009	3214083	16-Sep-2020
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Slovakia	17163383.7	23-Sep-2009	3214083	16-Sep-2020
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Slovenia	17163383.7	23-Sep-2009	3214083	16-Sep-2020
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Singapore	10201605492-Y	23-Sep-2009	10201605492Y	09-May-2018
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Singapore	2011020732	23-Sep-2009	169803	23-Aug-2016

PROCESS FOR MAKING	Sweden	17163383 7	23-Sen-2009	3214083
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Sweden	17163383.7	23-Sep-2009	3214083
PROCESS FOR MAKING	Russian Federation	2011116052	23-Sep-2009	2546667
QUINOLONE COMPOUNDS			,	
PROCESS FOR MAKING	Serbia	17163383.7	23-Sep-2009	3214083
QUINOLONE				
PROCESS FOR MAKING	Romania	17163383.7	23-Sep-2009	3214083
QUINOLONE			•	
PROCESS FOR MAKING	Portugal	17163383 7	73_Sen_2009	3714083
QUINOLONE	, Crubar		t c	
COMPOUNDS				
OUINOLONE	Poland	1/163383./	23-Sep-2009	3214083
COMPOUNDS				
PROCESS FOR MAKING OUINOLONE	Norway	17163383.7	23-Sep-2009	3214083
COMPOUNDS				
PROCESS FOR MAKING	Netherlands	17163383.7	23-Sep-2009	3214083
QUINOLONE COMPOUNDS				
PROCESS FOR MAKING	Netherlands	09816565.7	23-Sep-2009	2346855
QUINOLONE COMPOUNDS				
PROCESS FOR MAKING	Mexico	MX/a/2020/009790	23-Sep-2009	
QUINOLONE			٠	
PROCESS FOR MAKING	Mexico	MX/a/2015/000081	23-Sep-2009	377930
COMPOUNDS				

			7		7
Description	Country	App. No.	Filing Date	Patent No.	Issue Date
QUINOLONE	1416/2160	1417X/W/2011/0001777	10 00 1000	01000	11 1410 2010
COMPOUNDS					
PROCESS FOR MAKING	Malta	17163383.7	23-Sep-2009	3214083	16-Sep-2020
QUINOLONE			ı		1
COMPOUNDS					
PROCESS FOR MAKING	North Macedonia	17163383.7	23-Sep-2009	3214083	16-Sep-2020
COMPOUNDS					
PROCESS FOR MAKING	Monaco	17163383.7	23-Sep-2009	3214083	16-Sep-2020
QUINOLONE			,		,
COMPOUNDS					
PROCESS FOR MAKING	Latvia	17163383.7	23-Sep-2009	3214083	16-Sep-2020
COMPOUNDS					
PROCESS FOR MAKING	Luxembourg	17163383.7	23-Sep-2009	3214083	16-Sep-2020
COMPOLINDS					
PROCESS FOR MAKING	Lithuania	17163383.7	23-Sep-2009	3214083	16-Sep-2020
QUINOLONE					
COMPOUNDS					
PROCESS FOR MAKING	Korea, Republic of	10-2016-7026280	23-Sep-2009	1775304	30-Aug-2017
QUINOLONE					
PROCESS FOR MAKING	Ianan	2011-529013	23_Sen_2009	6013734	30 -S en-2016
QUINOLONE	1		ļ		,
COMPOUNDS					
PROCESS FOR MAKING	Italy	17163383.7	23-Sep-2009	3214083	16-Sep-2020
QUINOLONE			ı		
COMPOUNDS					
PROCESS FOR MAKING	Italy	7.59591860	23-Sep-2009	2346855	05-Apr-2017
QUINOLONE					
COMPONING					

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Iceland	17163383.7	23-Sep-2009	3214083	16-Sep-2020
PROCESS FOR MAKING QUINOLONE COMPOUNDS	India	1315/KOLNP/2011	23-Sep-2009	290385	07-Dec-2017
PROCESS FOR MAKING QUINOLONE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM	Israel	211845	23-Sep-2009	211845	01 -Jul- 2017
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Ireland	17163383.7	23-Sep-2009	3214083	16-Sep-2020
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Ireland	09816565.7	23-Sep-2009	2346855	05-Apr-2017
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Hungary	17163383.7	23-Sep-2009	3214083	16-Sep-2020
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Croatia	17163383.7	23-Sep-2009	3214083	16-Sep-2020
PHARMACEUTICAL FORMULATION CONTAINING A QUINOLONE DERIVATIVE	Hong Kong	42021035239.9	23-Sep-2009		
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Hong Kong	18103144.9	23-Sep-2009	HK1244481	16-Apr-2021
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Hong Kong	16101979.5	23-Sep-2009		

D escribed)	*			T D
PROCESS FOR MAKING	Hong Kong	11109814.2	23-Sep-2009	1155453	09-Mar-2018
QUINOLONE COMPOUNDS	(٠		
PROCESS FOR MAKING	Greece	17163383.7	23-Sep-2009	3214083	16-Sep-2020
QUINOLONE					
PROCESS FOR MAKING	United Kingdom	17163383.7	23-Sep-2009	3214083	16-Sep-2020
QUINOLONE			ı		
COMPOUNDS					
PROCESS FOR MAKING	United Kingdom	09816565.7	23-Sep-2009	2346855	05-Apr-2017
COMPOUNDS					
PROCESS FOR MAKING	France	17163383.7	23-Sep-2009	3214083	16-Sep-2020
QUINOLONE					
PROCESS FOR MAKING	France	09816565.7	23-Sep-2009	2346855	05-Apr-2017
QUINOLONE			,		,
COMPOUNDS					
PROCESS FOR MAKING	Finland	17163383.7	23-Sep-2009	3214083	16-Sep-2020
COMPOUNDS					
PROCESS FOR MAKING	Spain	17163383.7	23-Sep-2009	3214083	16-Sep-2020
QUINOLONE COMPOUNDS					
PROCESS FOR MAKING	Spain	09816565.7	23-Sep-2009	2346855	05-Apr-2017
QUINOLONE					
PROCESS FOR MAKING	European Patent	20191961	23-Sep-2009		
QUINOLONE COMPOUNDS	Convention				
PROCESS FOR MAKING	Estonia	17163383.7	23-Sep-2009	3214083	16-Sep-2020
COMPOUNDS					

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Denmark	17163383.7	23-Sep-2009	3214083	16-Sep-2020
PROCESS FOR MAKING QUINOLONE	Denmark	09816565.7	23-Sep-2009	2346855	05-Apr-2017
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Germany	17163383.7	23-Sep-2009	3214083	16-Sep-2020
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Germany	09816565.7	23-Sep-2009	2346855	05-Apr-2017
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Czech Republic	17163383.7	23-Sep-2009	3214083	16-Sep-2020
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Cyprus, Republic of	17163383.7	23-Sep-2009	3214083	16-Sep-2020
PROCESS FOR MAKING QUINOLONE COMPOUNDS	China (People's Republic)	200980138280.X	23-Sep-2009	ZL200980138280.X	19-Aug-2015
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Switzerland	17163383.7	23-Sep-2009	3214083	16-Sep-2020
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Switzerland	09816565.7	23-Sep-2009	2346855	05-Apr-2017
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Canada	2738236	23-Sep-2009	2738236	15-Nov-2016
PROCESS FOR MAKING QUINOLONE COMPOUNDS	Brazil	PI0919241-7	23-Sep-2009	PI0919241-7	12-May-2020

		haasaaaaaaaaaaaa			
Description	Country	App. No.	Filing Date	Patent No.	Issue Date
PROCESS FOR MAKING QUINOLONE	Bulgaria	17163383.7	23-Sep-2009	3214083	16-Sep-2020
COMPOUNDS					
PROCESS FOR MAKING	Belgium	17163383.7	23-Sep-2009	3214083	16-Sep-2020
QUINOLONE					
COMPOUNDS					
PROCESS FOR MAKING	Bosnia and	17163383.7	23-Sep-2009	3214083	16-Sep-2020
QUINOLONE	Herzegovina				
COMPOUNDS					
PROCESS FOR MAKING	Australia	2009297085	23-Sep-2009	2009297085	22-Oct-2015
QUINOLONE					
PROCESS FOR MAKING	Austria	17163383.7	23-Sep-2009	3214083	16-Sep-2020
QUINOLONE			ı		ı
PROCESS FOR MAKING	Alhania	17163383 7	23-Sen-2009	3214083	16-Sen-2020
QUINOLONE			Þ		-
COMPOUNDS					
THERAPEUTIC USES OF	United States of	16/828859	24-Mar-	11090319	17-Aug-2021
PHARMACEUTICAL	America		2020		
COMPRISING CYCLIC					
BORONIC ACID ESTER					
DERIVATIVES					
THERAPEUTIC USES OF	United States of	17/378248	16-Jul-2021		
PHARMACEUTICAL	America				
COMPOSITIONS					
COMPRISING CYCLIC					
BORONIC ACID ESTER					
DERIVATIVES					
CYCLIC BORONIC ACID	United States of	13/205112	08-Aug-	8680136	25-Mar-2014
ESTER DERIVATIVES	America		2011		
AND THERAPEUTIC USES					
THEREOF					

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
CYCLIC BORONIC ACID ESTER DERIVATIVES	United States of America	13/953647		9296763	29-Mar-2016
AND THERAPEUTIC USES THEREOF					
CYCLIC BORONIC ACID	United States of	15/015002	03-Feb-2016	9694025	04-Jul-2017
AND THERAPEUTIC USES	1 XIIICIICA				
THEREOF					
CYCLIC BORONIC ACID	United States of	15/624473	15-Jun-2017	10004758	26-Jun-2018
AND THERAPEUTIC USES					
THER APRITTIC HISES OF	United States of	15/035787	76-Mar-	10183034	22-Ian-2010
PHARMACEUTICAL	America	100000000000000000000000000000000000000	2018		
COMPOSITIONS					
BORONIC ACID ESTER					
DERIVATIVES					
PHARMACEUTICAL	United States of	15/935862	26-Mar-	10172874	08-Jan-2019
COMPOSITIONS	America		2018		
COMPRISING CYCLIC					
DERIVATIVES					
THERAPEUTIC USES OF	United States of	16/188982	13-Nov-	10639318	05-May-2020
PHARMACEUTICAL	America		2018		,
COMPOSITIONS					
COMPRISING CYCLIC					
BURUNIC ACID ESTER					
DERIVATIVES					
CYCLIC BORONIC ACID	United States of	13/843579	15-Mar-	10561675	18-Feb-2020
ESTER DERIVATIVES	America		2013		
AND THERAPEUTIC USES					
INENEUF					

Country	App. Ivo.	rimig Date	Fatent Ivo.	18 Mar 2021
ESTER DERIVATIVES America	10//+05/+	17-Jan-2020	1100/200	10-141ay-2021
JSES				
United States of 15/	15/305954	21-Oct-2016	10385074	20-Aug-2019
BORONATE SALTS AND America				,
United States of 16,	16/530625	02-Aug-	10669292	02-Jun-2020
BORONATE SALTS AND America		2019		
United States of 15/	15/309425	07-Nov-	9687497	27-Jun-2017
POLYMORPHS OF CYCLIC America		2016		
DERIVATIVES AND				
THERAPEUTIC USES				
United States of	15/537378	16-Jun-2017	10364257	30-Jul-2019
PROCESS FOR America				
PRODUCTION OF				
METHODS OF TREATING United States of BACTERIAL INFECTIONS America 16	16/029388	06-Jul-2018		
tates of	16/482195	30-Jul-2019	11312732	26-Apr-2022
AMILOTICA				
PRODUCTION OF				
APPARATUS AND United States of 17.	17/698719	18-Mar-		
CONTINUOUS FLOW America		2022		
PRODUCTION OF				

Description	Country	Ann No	Filing Date	Patent No	Issue Date
BORONIC ACID DERIVATIVE		=	q		
METHODS OF TREATING BACTERIAL INFECTIONS	United States of America	16/474487	27-Jun-2019		
METHODS OF TREATING BACTERIAL INFECTIONS	United States of America	16/753288	02-Apr-2020	11376237	05-Jul-2022
METHODS OF TREATING BACTERIAL INFECTIONS	United States of America	17/826712	27-May- 2022		
TETRACYCLINE COMPOSITIONS	United States of America	13/654018	17-Oct-2012	9278105	08-Mar-2016
TETRACYCLINE COMPOSITIONS	United States of America	14/204881	11-Mar- 2014	9084802	21-Jul-2015
TETRACYCLINE COMPOSITIONS	United States of America	16/287639	27-Feb-2019		
Cyclic boronic acid ester derivatives and therapeutic uses thereof	United States of America	16/746574	1/17/2020	11007206	05/18/2021
Antimicrobial compositions with effervescent agents	United States of America	16/774709	01/28/2020		
Process for the Synthesis of Triazoles	United States of America	11/921,838	1-Jun-2010	099668	19-Mar-2013
PROCESS FOR THE SYNTHESIS OF TRIAZOLES	Germany	06784685.7	08-Jun-2006	1904489	26-Jan-2011
PROCESS FOR THE SYNTHESIS OF TRIAZOLES	European Patent Convention	06784685.7	08-Jun-2006	1904489	26-Jan-2011
PROCESS FOR THE SYNTHESIS OF TRIAZOLES	France	06784685.7	08-Jun-2006	1904489	26-Jan-2011

Passilination)		מיני ביינים	Darant Nia	T Data
PROCESS FOR THE	United Kingdom	06784685.7	08-Jun-2006	1904489	26-Jan-2011
SYNTHESIS OF	,				
TRIAZOLES					
PROCESS FOR THE	United States of	13/845759	18-Mar-	8796465	05-Aug-2014
SYNTHESIS OF	America		2013		
TRIAZOLES					
PROCESS FOR THE	United States of	14/325248	07-Jul-2014	9376400	28-Jun-2016
SYNTHESIS OF	America				
TRIAZOLES					
COMPOUNDS AND	Albania	047/6193.7	02-Jun-2004	1656370	15-Aug-2012
METHODS OF MAKING					
AND USING THE SAME					
BIARYL HETEROCYCLIC	Austria	04776193.7	02-Jun-2004	1656370	15-Aug-2012
COMPOUNDS AND					
METHODS OF MAKING					
BIARYL HETEROCYCLIC	Belgium	04776193.7	02-Jun-2004	1656370	15-Aug-2012
COMPOUNDS AND	((
METHODS OF MAKING					
AND USING THE SAME					
BIARYL HETEROCYCLIC	Bulgaria	04776193.7	02-Jun-2004	1656370	15-Aug-2012
COMPOUNDS AND					
METHODS OF MAKING					
AND USING THE SAME	G-1-1	2520000	2004	2528080	24 31 - 2015
COMPOUNDS AND	Canada	23200089	02-Jun-2004	2328089	24-NOV-2013
METHODS OF MAKING					
AND USING THE SAME					
BIARYL HETEROCYCLIC	Switzerland	04776193.7	02-Jun-2004	1656370	15-Aug-2012
COMPOUNDS AND					
METHODS OF MAKING					
AND USING THE SAME					

C B	A M C B	P M O B	A M C B	A M O B	P M O B	A M O B	P M O B	A M C B	
BIARYL HETEROCYCLIC COMPOUNDS AND	BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	BIARYL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME	Description
France	Finland	Spain	European Patent Convention	Estonia	Denmark	Germany	Czech Republic	Cyprus, Republic of	Country
04776193.7	04776193.7	04776193.7	04776193.7	04776193.7	04776193.7	04776193.7	04776193.7	04776193.7	App. No.
02-Jun-2004	02-Jun-2004	02-Jun-2004	02-Jun-2004	02-Jun-2004	02-Jun-2004	02-Jun-2004	02-Jun-2004	02-Jun-2004	Filing Date
1656370	1656370	1656370	1656370	1656370	1656370	1656370	1656370	1656370	Patent No.
15-Aug-2012	15-Aug-2012	15-Aug-2012	15-Aug-2012	15-Aug-2012	15-Aug-2012	15-Aug-2012	15-Aug-2012	15-Aug-2012	Issue Date

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
METHODS OF MAKING AND USING THE SAME					
BIARYL HETEROCYCLIC COMPOUNDS AND	United Kingdom	04776193.7	02-Jun-2004	1656370	15-Aug-2012
METHODS OF MAKING					
BIARYL HETEROCYCLIC	Greece	04776193.7	02-Jun-2004	1656370	15-Aug-2012
COMPOUNDS AND					· (
METHODS OF MAKING					
BIARYL HETEROCYCLIC	Hungary	04776193.7	02-Jun-2004	1656370	15-Auε-2012
COMPOUNDS AND	,				(
METHODS OF MAKING					
BIARYI, HETEROCYCIJC	Ireland	04776193 7	02-Jun-2004	1656370	15-Ano-2012
COMPOUNDS AND					(
METHODS OF MAKING					
AND USING THE SAME	T1	04776102 7	02 1 2004	1/5/270	15 1 2012
COMPOUNDS AND	iwi)		1000	10000	to true port
METHODS OF MAKING					
AND USING THE SAME					
BIARYL HETEROCYCLIC	Luxembourg	04776193.7	02-Jun-2004	1656370	15-Aug-2012
METHODS OF MAKING					
AND USING THE SAME					
BIARYL HETEROCYCLIC	Latvia	04776193.7	02-Jun-2004	1656370	15-Aug-2012
COMPOUNDS AND					
METHODS OF MAKING					
AND USING THE SAME					
BIARYL HETEROCYCLIC	Monaco	04776193.7	02-Jun-2004	1656370	15-Aug-2012
COMPOUNDS AND					
METHODS OF MAKING					
AND USING THE SAME					

L				I diciil ino.	
BIARYL HETEROCYCLIC	North Macedonia	04776193.7	02-Jun-2004	1656370	15-Aug-2012
METHODS OF MAKING					
AND USING THE SAME					
BIARYL HETEROCYCLIC	Mexico	PA/a/2005/013132	02-Jun-2004	277105	06-Jul-2010
COMPOUNDS AND					
METHODS OF MAKING					
AND USING THE SAME					
BIARYL HETEROCYCLIC	Mexico	MX/a/2010/007366	02-Jun-2004	318047	14-Feb-2014
COMPOUNDS AND					
METHODS OF MAKING					
AND USING THE SAME					
BIARYL HETEROCYCLIC	Netherlands	04776193.7	02-Jun-2004	1656370	15-Aug-2012
COMPOUNDS AND					
METHODS OF MAKING					
AND USING THE SAME					
BIARYL HETEROCYCLIC	Poland	04776193.7	02-Jun-2004	1656370	15-Aug-2012
COMPOUNDS AND					
METHODS OF MAKING					
AND USING THE SAME					
BIARYL HETEROCYCLIC	Portugal	04776193.7	02-Jun-2004	1656370	15-Aug-2012
COMPOUNDS AND					
METHODS OF MAKING					
AND USING THE SAME					
BIARYL HETEROCYCLIC	Romania	04776193.7	02-Jun-2004	1656370	15-Aug-2012
COMPOUNDS AND					,
METHODS OF MAKING					
AND USING THE SAME					
BIARYL HETEROCYCLIC	Sweden	04776193.7	02-Jun-2004	1656370	15-Aug-2012
COMPOUNDS AND					
METHODS OF MAKING					
AND USING THE SAME					
BIARYL HETEROCYCLIC	Slovenia	04776193.7	02-Jun-2004	1656370	15-Aug-2012
COMPOUNDS AND					

Description	Country	App. No.	Filing Date	Patent No.
METHODS OF MAKING AND USING THE SAME				
BIARYL HETEROCYCLIC	Slovakia	04776193.7	02-Jun-2004	1656370
COMPOUNDS AND				
METHODS OF MAKING				
AND USING THE SAME				
BIARYL HETEROCYCLIC	Turkey	04776193.7	02-Jun-2004	1656370
COMPOUNDS AND	,			
METHODS OF MAKING				
AND USING THE SAME				
BIARYL HETEROCYCLIC	United States of	14/280972	19-May-	9550783
COMPOUNDS AND	America		2014	
METHODS OF MAKING				
AND USING THE SAME				
BIARYL HETEROCYCLIC	United States of	10/859476	02-Jun-2004	6969726
COMPOUNDS AND	America			
METHODS OF MAKING				
AND USING THE SAME				
BIARYL HETEROCYCLIC	United States of	11/118808	29-Apr-2005	7148219
COMPOUNDS AND	America			
METHODS OF MAKING				
AND USING THE SAME				
BIARYL HETEROCYCLIC	United States of	11/486769	14-Jul-2006	7456206
COMPOUNDS AND	America			
METHODS OF MAKING				
AND USING THE SAME				
BIARYL HETEROCYCLIC	United States of	12/275941	21-Nov-	7705026
COMPOUNDS AND	America		2008	
METHODS OF MAKING				
AND USING THE SAME				
HALOGENATED BIARYL	United States of	11/001446	01-Dec-2004	7129259
HETEROCYCLIC	America			
COMPOUNDS AND				
METHODS OF MAKING				

Description	Country	App. No.	Filino Date	Patent No.	Issue Date
AND USING THE SAME					
PROCESS FOR SYNTHESIS	Switzerland	04779405.2	28-Jul-2004	1660465	17-Dec-2014
OF BIARYL					
OXAZOLIDINONES					
PROCESS FOR SYNTHESIS	Germany	04779405.2	28-Jul-2004	1660465	17-Dec-2014
OF BIARYL	,				
OXAZOLIDINONES					
PROCESS FOR SYNTHESIS	European Patent	04779405.2	28-Jul-2004	1660465	17-Dec-2014
OF BIARYL	Convention				
OXAZOLIDINONES					
PROCESS FOR SYNTHESIS	Spain	04779405.2	28-Jul-2004	1660465	17-Dec-2014
OF BIARYL					
OXACOLIDINONES					
PROCESS FOR SYNTHESIS	France	04779405.2	28-Jul-2004	1660465	17-Dec-2014
OX AZOI IDINONES					
PROCESS FOR SYNTHESIS	United Kingdom	04779405.2	28-Jul-2004	1660465	17-Dec-2014
OF BIARYL	(
OXAZOLIDINONES					
PROCESS FOR THE	United States of	10/566150	07-Oct-2009	8324398	04-Dec-2012
SYNTHESIS OF BIARYL	America				
OXAZOLIDINONES					
PROCESS FOR THE	United States of	13/618091	14-Sep-2012	8895741	25-Nov-2014
SYNTHESIS OF BIARYL	America				
OXAZOLIDINONES					
PHARMACEUTICAL	Austria	11838664.8	01-Nov-	2635307	29-Jul-2020
COMPOSITIONS			2011		
PHARMACEUTICAL	Belgium	11838664.8	01-Nov-	2635307	29-Jul-2020
COMPOSITIONS	,		2011		
ANTIMICROBIAL	Canada	2816077	01-Nov-	2816077	10-Aug-2021
COMPOSITIONS COMPRISING AN			2011		

Country App. No. Filing Date Switzerland 11838664.8 01-Nov- Germany 11838664.8 01-Nov- European Patent 11838664.8 01-Nov- Convention 11838664.8 01-Nov- Spain 11838664.8 01-Nov- France 11838664.8 01-Nov- 2011 2011
01-Nov- 2011 01-Nov- 2011 01-Nov- 2011 01-Nov- 2011

Description	Country	Ann No.	Filino Date	Patent No.	Issue Date
PHARMACEUTICAL COMPOSITIONS	Sweden	11838664.8	01-Nov- 2011	2635307	29-Jul-2020
SUSTAINED RELEASE PHARMACEUTICAL	United States of America	13/882698	16-Dec-2013	9409896	09-Aug-2016
COMPOSITIONS					
COMPRISING AN					
ANTIBACTERIAL AGENT					
PHARMACEUTICAL	Mexico	MX/a/2012/004282	12 -Oct- 2010	337145	15-Feb-2016
COMPOSITIONS OF					
ANTIMICROBIAL AGENTS					
PHARMACEUTICAL COMPOSITIONS	Austria	11843190.7	21-Nov- 2011	2642996	23-Sep-2020
PHARMACEUTICAL COMPOSITIONS	Belgium	11843190.7	21-Nov- 2011	2642996	23-Sep-2020
PHARMACEUTICAL COMPOSITIONS COMPRISING RADEZOLID,	Canada	2818249	21-Nov- 2011	2818249	13-Apr-2021
HYDROXPROPLYMETHYL CELLULOSE POLYMER, AND A PHYSICAL MIXTURE					
PHARMACEUTICAL COMPOSITIONS	Switzerland	11843190.7	21-Nov- 2011	2642996	23-Sep-2020
PHARMACEUTICAL COMPOSITIONS	Germany	11843190.7	21-Nov- 2011	2642996	23-Sep-2020
PHARMACEUTICAL COMPOSITIONS	European Patent Convention	11843190.7	21-Nov- 2011	2642996	23-Sep-2020
PHARMACEUTICAL COMPOSITIONS	Spain	11843190.7	21-Nov- 2011	2642996	23-Sep-2020

Description	Country	Ann No	Filing Date	Patent No	Icena Data
PHARMACEUTICAL COMPOSITIONS	France	11843190.7	21-Nov- 2011	2642996	23-Sep-2020
PHARMACEUTICAL COMPOSITIONS	United Kingdom	11843190.7	21-Nov- 2011	2642996	23-Sep-2020
PHARMACEUTICAL COMPOSITIONS	Greece	11843190.7	21-Nov- 2011	2642996	23-Sep-2020
PHARMACEUTICAL COMPOSITIONS	Hungary	11843190.7	21-Nov- 2011	2642996	23-Sep-2020
PHARMACEUTICAL COMPOSITIONS	Ireland	11843190.7	21-Nov- 2011	2642996	23-Sep-2020
PHARMACEUTICAL COMPOSITIONS	Italy	11843190.7	21-Nov- 2011	2642996	23-Sep-2020
PHARMACEUTICAL COMPOSITIONS	Japan	2013-540991	21-Nov- 2011	6370550	20-Jul-2018
PHARMACEUTICAL COMPOSITIONS	Mexico	MX/a/2013/005813	21-Nov- 2011	350565	11-Sep-2017
PHARMACEUTICAL COMPOSITIONS	Portugal	11843190.7	21-Nov- 2011	2642996	23-Sep-2020
PHARMACEUTICAL COMPOSITIONS	Sweden	11843190.7	21-Nov- 2011	2642996	23-Sep-2020
PHARMACEUTICAL COMPOSITIONS	United States of America	15/260424	09-Sep-2016	10300046	28-May-2019
METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION	Canada	2967825	16-Nov- 2015		
METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION	European Patent Convention	15858675.0	16-Nov- 2015		

Description	Country	App. No.	Filing Date	Patent No.	Issue Date
METHOD FOR TREATING, PREVENTING, OR REDUCING THE RISK OF SKIN INFECTION	Mexico	MX/a/2017/006319	16-Nov- 2015	389005	03-Jan-2022
METHOD FOR TREATING, PREVENTING, OR	United States of America	14/942021	16-Nov- 2015	10471046	12-Nov-2019
REDUCING THE RISK OF SKIN INFECTION					
TOPICAL	Canada	3024531	16-May-		
FORMULATIONS OF BIARYL HETEROCYCLIC			2017		
COMPOUNDS AND					
THEREOF					
TOPICAL FORMER OF	European Patent	17727439.6	16-May- 2017		
BIARYL HETEROCYCLIC					
METHODS OF USE					
THEREOF					
TOPICAL FORMULATIONS OF	Hong Kong	19127619.5	16-May- 2017		
BIARYL HETEROCYCLIC					
AND METHODS OF USE					
THEREOF					
TOPICAL	Mexico	MX/a/2018/013994	16-May-		
FORMULATIONS OF			2017		
COMPOUNDS					
AND METHODS OF USE					
111111111111111111111111111111111111111					

TRADEMARK

REEL: 007821 FRAME: 0473

EXHIBIT C

Trademarks

Trademark	Country Name	App No.	App. Date	Reg. No.	Reg. Date
BAXDELA	United States of America	86707152	7/28/2015	5561401	9/11/2018
::Baxdela	United States of America	88058147	7/30/2018	5725767	4/16/2019
MELINTA	United States of America	86063824	9/13/2013	4653983	12/9/2014
MELINTA THE ANTIBIOTICS COMPANY	United States of America	86688547	7/9/2015	4939738	4/19/2016
MELINTA THERAPEUTICS	Canada	1653645	11/26/2013	TMA949637	9/19/2016

Trademark	Country Name	App No.	App. Date	Reg. No.	Reg. Date
MELINTA THERAPEUTICS	European Union (Community)	12340634	11/25/2013	12340634	4/24/2014
MELINTA THERAPEUTICS	Japan	2013094683	12/3/2013	5672516	5/23/2014
MELINTA THERAPEUTICS	Mexico	M1435929	11/27/2013	1447784	4/21/2014
MELINTA THERAPEUTICS	United Kingdom	912340634	11/25/2013	912340634	4/24/2014
MELINTA THERAPEUTICS	United States of America	86063818	9/13/2013	4713360	3/31/2015
MELINTASSIST	United States of America	87615784	9/20/2017	5752179	5/14/2019

RECORDED: 08/25/2022

Trademark	Country Name	App No.	App. Date	Reg. No.	Reg. Date
MELINTASSIST	United States of America	87666296	10/31/2017	5662658	1/22/2019